RogerCInhornMDPhD

Oncology • Portland, ME

Medical Director, Mercy Hospital Oncology/Hematology

Join to view full profile

Dr. Inhorn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Inhorn's full profile

Already have an account?

Office
144 State St
Portland, ME 04101
Phone+1 207-879-3000
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1994
Brigham and Women's HospitalResidency, Internal Medicine, 1990 - 1993
Washington University in St. Louis School of MedicineClass of 1990

Certifications & Licensure

ME State Medical License 2004 - 2024
IL State Medical License 1997 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
Active, not recruiting
Phase 3
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).
Eric C Anderson, John DiPalazzo, F Lee Lucas, Michael J Hall, Andrey Antov, Petra Helbig, Jennifer Bourne, Leah Graham, Lory Gaitor, Christine Lu-Emerson, Leslie S Bra...> ;NPJ Precision Oncology. 2024 Mar 9
Improved Overall Survival of Patients with Pancreatic Cancer through Multiagent Chemotherapy and Increased Rates of Surgical Resection.
Abdimajid Mohamed, Dougald Macgillivray, Nicholas Verdini, Roger Inhorn, Matthew Dugan, Cynthia M Hayward, Timothy L Fitzgerald, Laura M Nicolais> ;The American Surgeon. 2023 Dec 1
1 citations
The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State.
Jens Rueter, Eric C Anderson, Leah C Graham, Andrey Antov, Petra Helbig, Lory Gaitor, Jennifer Bourne, Emily Edelman, E Kate Reed, Honey V Reddi, Susan Mockus, John Di...> ;JCO Precision Oncology. 2023 May 1
17 citations
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
Denise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky, David Drosick, Fred J. Kudrik, Linda D. Bosserman, Mark Keaton, Sharon A. Goble,...> ;Breast Cancer Research and Treatment. 2017 May 15
10 citations
Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
Denise A. Yardley, Natalie R. Dickson, David Drosick, Chris Earwood, Roger Inhorn, Patrick B. Murphy, John D. Hainsworth> ;Clinical Breast Cancer. 2016 Jun 1
17 citations
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced ...
Denise A. Yardley, John D. Zubkus, Brooke R. Daniel, Roger Inhorn, Cassie M. Lane, Elizabeth R. Vazquez, Yuval Naot, Howard A. Burris, John D. Hainsworth> ;Clinical Breast Cancer. 2010 Oct 1
8 citations
Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
David R. Spigel, F. Anthony Greco, Dana S. Thompson, Charles D. Webb, James R. Rubinsak, Roger Inhorn, James A. Reeves, Elizabeth R. Vazquez, Cassie M. Lane, Howard A....> ;Clinical Lung Cancer. 2010 May 1
Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in...
Raefsky E, Inhorn R, Lange M, Peacock N, Shastry M, Vazquez E, Priego V, Franco L, Hainsworth JD, Yardley DA> ;J. Clin. Oncol.. 2009-05-20
Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel.
Inhorn RC, Daniel B, Daniel D, Naot Y, Zubkus J, Lane C, Trieu V, Knauer D, Desai N, Yardley DA> ;J. Clin. Oncol.. 2009-05-20
Phase II study of neoadjuvant gemcitabine, epirubicin, and albumin-bound nab paclitaxel (GEA) in locally advanced breast cancer with SPARC tumor assessments.
Yardley DA, Inhorn RC, Daniel D, Daniel B, Naot Y, Zubkus J, Simons L, Knauer D, Trieu V, Desai N> ;J. Clin. Oncol.. 2008-05-20
Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC).
Rubinsak JR, Spigel DR, Hainsworth JD, Webb C, Inhorn RC, Infante JR, Yardley DA, Burris HA, Vazquez ER, Greco FA> ;J. Clin. Oncol.. 2008-05-20
69 citations
The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner
Kai Xia, Nishit K. Mukhopadhyay, Roger C. Inhorn, Dwayne L. Barber, P. E. Rose, Robert Lee, Radha P. Narsimhan, Alan D. D'Andrea, James D. Griffin, Thomas M. Roberts> ;Proceedings of the National Academy of Sciences of the United States of America. 1996 Oct 15
46 citations
The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor.
Yuan Zhu, Miklos Pless, Roger C. Inhorn, Bernard Mathey-Prevot, Alan D. D'Andrea> ;Molecular and Cellular Biology. 1996 Sep 1
30 citations
Tyrosine phosphorylation of Shc is not required for proliferation or viability signaling by granulocyte-macrophage colony-stimulating factor in hematopoietic cell lines.
M. Durstin, Roger C. Inhorn, James D. Griffin> ;Journal of Immunology. 1996 Jul 15
46 citations
Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750.
Roger C. Inhorn, Nadia Carlesso, M. Durstin, David A. Frank, James D. Griffin> ;Proceedings of the National Academy of Sciences of the United States of America. 1995 Sep 12
114 citations
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic...
Roger C. Inhorn, Jon C. Aster, Sheila A. Roach, Christopher A. Slapak, Robert J. Soiffer, Ramana Tantravahi, Richard Stone> ;Blood. 1995 Apr 1
122 citations
Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL.
Tetsuya Matsuguchi, Roger C. Inhorn, Nadia Carlesso, Gang Xu, Brian Druker, James D. Griffin> ;The EMBO Journal. 1995 Jan 16
40 citations
A low affinity chimeric human alpha/beta-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line.
M. Eder, T.J. Ernst, Arnold Ganser, P.T. Jubinsky, R. Inhorn, Dieter Hoelzer, James D. Griffin> ;The Journal of Biological Chemistry. 1994 Dec 2
17 citations
Properties of inositol polyphosphate 1-phosphatase.
R C Inhorn, P W Majerus> ;The Journal of Biological Chemistry. 1988 Oct 5
45 citations
Inositol phosphates: synthesis and degradation.
P W Majerus, T M Connolly, V S Bansal, R C Inhorn, T S Ross, D L Lips> ;The Journal of Biological Chemistry. 1988 Mar 5
35 citations
Phosphorylation of vitronectin by a protein kinase in human plasma. Identification of a unique phosphorylation site in the heparin-binding domain.
Elizabeth A. McGuire, M E Peacock, Roger C. Inhorn, N R Siegel, Douglas M. Tollefsen> ;The Journal of Biological Chemistry. 1988 Feb 5
20 citations
Inositol polyphosphate 1-phosphatase from calf brain. Purification and inhibition by Li+, Ca2+, and Mn2+.
R C Inhorn, P W Majerus> ;The Journal of Biological Chemistry. 1987 Nov 25
6 citations
The metabolism of inositol 1,3,4-trisphosphate to inositol 1,3-bisphosphate.
V S Bansal, R C Inhorn, P W Majerus> ;The Journal of Biological Chemistry. 1987 Jul 15
5 citations
Pathway for inositol 1,3,4-trisphosphate and 1,4-bisphosphate metabolism.
R C Inhorn, V S Bansal, P W Majerus> ;Proceedings of the National Academy of Sciences of the United States of America. 1987 Apr 1
17 citations
Isolation and characterization of a partial cDNA clone for heparin cofactor II
Roger C. Inhorn, Douglas M. Tollefsen> ;Biochemical and Biophysical Research Communications. 1986 May 29
Join now to see all

Press Mentions

4 Oncologists on the MoveJanuary 28th, 2022
MaineHealth Launches Comprehensive Medical Oncology Practice in Biddeford, SacoOctober 6th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Northern Light Mercy HospitalPortland, Maine
Maine Veterans Affairs Medical CenterAugusta, Maine
Maine Medical CenterPortland, Maine